| Similar Articles |
|---|
 |
The Motley Fool
June 24, 2008
Brian Lawler |
Barrier Taken Down Barrier Therapeutics announces that Stiefel Labs will buy them for $148 million.   |
The Motley Fool
May 28, 2008
Brian Lawler |
No Barrier to Deals Like This In the latest example of overlap between the pharmaceutical and consumer-health care industries, Barrier Therapeutics announces that it will package one of its lead prescription drugs with a shampoo sold by Procter & Gamble. |
The Motley Fool
June 15, 2011
Brian Orelli |
Investors Need a Peephole Into FDA Offices Cell Therapeutics is gung ho about its resubmission, but investors only get one side of the story. |
The Motley Fool
December 31, 2011
David Williamson |
2011 Review: Cell Therapeutics After starting the year at a split-adjusted $2.22 a share, Cell Therapeutics stock lost almost 50% of its value by the end of December, closing at $1.16. How did we get here? |
The Motley Fool
January 13, 2004
Jeff Hwang |
Eon Labs' Potent Potential The generic drug maker's fourth-quarter estimates spiked higher. |
The Motley Fool
May 4, 2011
Brian Orelli |
Cell Therapeutics: Denied but Not Rejected Cell Therapeutics' ball may be headed for the end zone, but the FDA has an eight-foot free safety ready to bat it down. |
The Motley Fool
September 28, 2011
Brian Orelli |
One Step Closer to an FDA Decision Cell Therapeutics is still risky, though. |
The Motley Fool
May 27, 2011
Brian Orelli |
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. |
The Motley Fool
January 4, 2012
Brian Orelli |
Mark Your Calendars, Biotech Investors Cell Therapeutics' advisory panel meet ought to be entertaining. |
The Motley Fool
September 15, 2010
Brian Orelli |
Cell Therapeutics Goes for Broke If Cell Therapeutics can't get new funding soon, long-term consequences may be the least of its worries; time on the clock looks to be running out. |
The Motley Fool
January 30, 2007
Brian Lawler |
Par Passes the Generic Bar Par Pharmaceutical Companies gets approval to market another generic product, but the company still has to complete the restatement of its past financials. Investors, take note. |
The Motley Fool
July 29, 2011
Sean Williams |
Another Day, Another Loss For Cell Therapeutics Cell Therapeutics is giving shareholders that sinking feeling. |
The Motley Fool
September 17, 2010
Luke Timmerman |
Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders? |
The Motley Fool
June 15, 2005
Brian Gorman |
Cell Therapeutics' Gamble The biotech company's struggles are far from over. Without an approved drug on the market or the certainty of FDA clearance, the firm won't have an easy time finding investors. |
Managed Care
September 2006 |
Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association. |
Managed Care
February 2008
Martin Sipkoff |
FDA Approach to Generics May Be a Mixed Blessing A recently announced initiative is supposed to speed approval of generic drugs, but does it address some fundamental flaws in the approval process? |
The Motley Fool
July 1, 2011
Brian Orelli |
What Will Cell Therapeutics Do With Your Money? Unfortunately the answer is probably, "buying a drug." |
The Motley Fool
October 16, 2006
Brian Lawler |
The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note. |
American Family Physician
May 1, 2004 |
Vaginal Yeast Infections A general overview on vaginal yeast infections. |
